APA (7th ed.) Citation

Leclercq, M., Andrillon, A., Maalouf, G., Sève, P., Bielefeld, P., Gueudry, J., . . . Saadoun, D. (2022). Anti-Tumor Necrosis Factor α versus Tocilizumab in the Treatment of Refractory Uveitic Macular Edema: A Multicenter Study from the French Uveitis Network. Ophthalmology (Rochester, Minn.), 129(5), 520-529. https://doi.org/10.1016/j.ophtha.2021.11.013

Chicago Style (17th ed.) Citation

Leclercq, Mathilde, et al. "Anti-Tumor Necrosis Factor α Versus Tocilizumab in the Treatment of Refractory Uveitic Macular Edema: A Multicenter Study from the French Uveitis Network." Ophthalmology (Rochester, Minn.) 129, no. 5 (2022): 520-529. https://doi.org/10.1016/j.ophtha.2021.11.013.

MLA (9th ed.) Citation

Leclercq, Mathilde, et al. "Anti-Tumor Necrosis Factor α Versus Tocilizumab in the Treatment of Refractory Uveitic Macular Edema: A Multicenter Study from the French Uveitis Network." Ophthalmology (Rochester, Minn.), vol. 129, no. 5, 2022, pp. 520-529, https://doi.org/10.1016/j.ophtha.2021.11.013.